Look agoing to. No legislation. Whenever a 5593 page covid relief bill is, its not a law. None of the socalled legislators of the socalled Legislative Branch right or read their own, quote, legislation. I used to be naive enough to think these perversions of laugh were at least written by staffers. Like that nice lady who sits next to Chuck Schumer who looks her best to be dazzled by his rhetoric. My best guess now its a google algorithm. The lobbyists enter their wish list at stiff the citizenry. Com and then the algorithm turns it all together and you find out you are getting 60 bucks for every month you havent been allowed to open your gym or hair salon and some Village Hedman in who gives astan 30 times that take your child bride to work day promotion. Its not a parliament. Its not legislature not a citadel of democracy. Its a Per Severitied will dungeon of democracy you are hanging upside down and no safe word. Last night we finally found out what the citadel of democracy is a cit
Consumer in this covid economy and a ventilator boost from medtronic, but sales for other medical devices remain lower medtronics ceo will join us exclusively later this hour. Carl, jims shaking his head already. I dont know speculative market ive ever seen i was going to say, jim, i mean, what a confluence of headlines and then to layer on what you were talking about with becky, this seemingly endless generational bid for stocks in general. You know, look at these plug power did a deal last week, 38 million shares of 22. 25, norwegian did a deal of 40 million shares at 20. 80, carnival did a huge deal at 17. 59, up huge on that, American Airlines did a deal, huge amount of stock, and about price that is a dollar below where this it is trading. Ive never seen anything like it where are the profit takers . Where are they i dont know. This is listen, we have been talking about this new cohort in the market, theyre for real, man. They are real it is not just ev stocks that are ev Companie
As far as the current state of play, these past three weeks we have seen three crucial positive readouts of data from leading programs. The first came from pfizer, the second came from moderna, and the third one this morning just came from astrazeneca and the team at oxford. These are three leading vaccine front runners, all three in late stage studies appear to be effective, the first to 95 effective in preventing covid19. Thatnity is expected to do late november, early december. That will set up an fda decision, all eyes turning to the agency to see how quickly they can approve it and for what subgroups of the population. Vaccineing on in the phase, but there is a lot going on and muchneeded positive news when you think about the surge that we have seen in cases, hospitalizations, and deaths. The fda approval, how quickly could they approve it, and what could keep them from being approved, and how is the fda ensuring confidence in the public in the safety of these vaccines . Guest i
Phone lines split up as usual this morning. Democrats, 202 7488000 is the number to call in. Republicans, 202 7488001. Independents, 202 7488002. You can also send us a text. That number, 202 7488003. If you do, please include your name and where you are from. You can catch up with us on social media, twitter and facebook. A very good monday morning to you. You can start calling in now. Theheadlines on this topic, first use of the vaccine maybe december 13. 40 million doses said to be available by the end of the month. That from the front page of usa today. Frontline gets the first vaccine doses, but then who . Thats the question we are asking this morning, asking you to be in the position of setting the priority, how would you do it . Turning to the cdc webpage there, i q a on how the cdc is making its covid19 vaccine recommendations. Making those disease vaccine recommendations based on the input from the Advisory Committee on immunization practices. Its a federal Advisory Committee
Here on cspan. Is the Health Care Reporter focusing on the pharmaceutical biotech industry for Business Insider and joins us via zoom for a deep dive into the topic of Coronavirus Vaccine. It has been hard to keep up with the news of the past two weeks. Take us through what you expect in the coming days and weeks. What we should be watching for this week. Guest thanks for having me, john. That makes two of us as far as trying to keep on top of everything. As far as the current state of play, these past three weeks we have seen three crucial positive readouts of data from leading programs. The first came from pfizer, the second came from moderna, and the third one this morning just came from astrazeneca and the team at oxford. These are three leading vaccine front runners, all three in late stage studies appear to be effective, the first to 95 effective in preventing covid19. Thatnity is expected to do late november, early december. That will set up an fda decision, all eyes turning to